HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A contemporary comparison of aortofemoral bypass and aortoiliac stenting in the treatment of aortoiliac occlusive disease.

AbstractBACKGROUND:
Although aortofemoral bypass (AFB) has historically been the treatment of choice for aortoiliac occlusive disease (AIOD), rates of AFB have declined, while utilization of aortoiliac angioplasty and stenting (AS) has increased dramatically. The objective of the current study was to determine the effect of these trends on treatment outcomes in a contemporary single-institution experience with AIOD.
METHODS:
Between 1997 and 2007, 118 AFB and 174 AS procedures were performed in 161 men (55.1%) and 131 women at a single university teaching hospital. Patient outcomes were retrospectively reviewed and analyses were performed using chi-squared/Fisher's exact test and ANOVA. Ankle-brachial index (ABI) interactions between procedure type and Trans-Atlantic Inter-Society Consensus (TASC) category were calculated using a General Linear Model. A reduced Cox model was used to determine the impact of patency, presenting symptoms, duplex surveillance, and procedure type on amputations and revisions. Kaplan-Meier estimates for survival, freedom from amputation, and freedom from revision were used to evaluate long-term outcomes.
RESULTS:
There was no difference between AFB and AS groups with respect to 30-day mortality (0.8% and 1.1%, p=0.64), myocardial infarction (1.7% and 1.1%, p=0.53), cerebrovascular accident (0.0% and 1.1%, p=0.35), or renal failure requiring hemodialysis (3.4% and 1.2%, p=0.19). AFB was associated with increased surgical complication rates including the need for emergency surgery (6.8% and 1.7%, p=0.029), infection/sepsis (16.1% and 2.3%, p<0.001), transfusion (16.1% and 5.7%, p=0.004), and lymph leak (8.5% and 0.6%, p=0.001). The difference between preprocedural and postprocedural ABI was greater for AFB than AS (R, 0.39 and 0.18, p<0.001; L, 0.41 and 0.15, p<0.001). This difference was maintained when patients were stratified by TASC category.
CONCLUSION:
There were no differences between the AFB and AS groups with respect to long-term rates of mortality, amputation, or revision procedures. AFB continues to be performed safely, despite the case numbers in this series correlating with a lower-volume hospital. Morbidities associated with major open surgery in this series were counterbalanced by greater improvements in ABI. Patients and practitioners should continue to entertain both procedure types as viable alternatives for the treatment of AIOD.
AuthorsChristopher R Burke, Peter K Henke, Roland Hernandez, John E Rectenwald, Venkat Krishnamurthy, Michael J Englesbe, James J Kubus, Guillermo A Escobar, Gilbert R Upchurch Jr, Jonathan L Eliason
JournalAnnals of vascular surgery (Ann Vasc Surg) Vol. 24 Issue 1 Pg. 4-13 (Jan 2010) ISSN: 1615-5947 [Electronic] Netherlands
PMID20122461 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
Topics
  • Amputation, Surgical
  • Anastomosis, Surgical
  • Angioplasty (adverse effects, instrumentation, mortality)
  • Ankle (blood supply)
  • Aortic Diseases (diagnostic imaging, mortality, physiopathology, surgery, therapy)
  • Aortography
  • Arterial Occlusive Diseases (diagnostic imaging, mortality, physiopathology, surgery, therapy)
  • Blood Pressure
  • Brachial Artery (physiopathology)
  • Chi-Square Distribution
  • Constriction, Pathologic
  • Female
  • Hospitals, University
  • Humans
  • Iliac Artery (diagnostic imaging, physiopathology, surgery)
  • Kaplan-Meier Estimate
  • Limb Salvage
  • Linear Models
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Reoperation
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Stents
  • Time Factors
  • Treatment Outcome
  • Vascular Surgical Procedures (adverse effects, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: